ClinicalTrials.gg
RecruitingNCT06989723Updated May 25, 2025

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

A Phase 4 interventional study of Pioglitazone 15 MG [Actos] and Empagliflozin 10 MG [Jardiance] in Type 2 Diabetes and Fatty Liver, sponsored by Seoul National University Bundang Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Seoul National University Bundang Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2025, registered Apr 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Planned enrollment
54th of 122
120 · median 103
Started
2025
with 2 others
Phase 4
57 of 122
4 open now
Registered
121st of 122
by date

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 54th largest by planned enrollment, is one of 3 that started in 2025, is one of 57 in phase 4, and was the 121st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.

03

Conditions studied

  • Type 2 Diabetes
  • Fatty Liver
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 20 years or older.
  2. Patients with inadequately controlled type 2 diabetes mellitus, defined as between 7% and 10%, who are currently treated with either:

    • Combination therapy of metformin and a sulfonylurea, or
    • Combination therapy of metformin and a DPP-4 inhibitor, or
    • Metformin monotherapy, or
    • Triple therapy (including metformin) provided that sulfonylurea will be discontinued upon study enrollment.
  3. Evidence of hepatic steatosis within the past 3 months, confirmed by Fibroscan with a controlled attenuation parameter (CAP) ≥ 268 dB/m (consistent with S2 or greater [≥10% hepatocyte steatosis] according to the 2024 EASL-EASD-EASO guidelines).
  4. Presence of at least one of the following metabolic abnormalities:

    • Waist circumference ≥90 cm for men or ≥85 cm for women.
    • Blood pressure ≥130 mmHg systolic or ≥85 mmHg diastolic, or use of antihypertensive medication.
    • Serum triglycerides ≥150 mg/dL or current use of lipid-lowering agents.
    • HDL-cholesterol ≤45 mg/dL for men or ≤50 mg/dL for women.
    • HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) ≥2.5.
    • Serum C-reactive protein (CRP) ≥2 mg/L.
  5. No changes in anti-diabetic or metabolic medications within the past 3 months, unless the changes are deemed by the investigator not to affect study outcomes.

Exclusion criteria

Exclusion Criteria:

  1. Patients receiving insulin therapy or diagnosed with type 1 diabetes mellitus.
  2. Use of the following medications within the past 3 months: GLP-1 receptor agonists, SGLT2 inhibitors, rosiglitazone (TZD), vitamin E, or ursodeoxycholic acid (UDCA).
  3. Presence of secondary causes of hepatic steatosis unrelated to metabolic dysfunction, such as , , or alcoholic fatty liver disease.
  4. Use of medications known to induce hepatic steatosis, including valproic acid, estrogen, tamoxifen, amiodarone, or chloroquine.
  5. Severe organ failure, defined as:

    • Liver failure: or ALT > 5 times the upper normal limit (UNL), serum albumin \< 3.2 g/dL, count \< 60,000/µL, or -Turcotte stage B or C.
    • Renal failure: Serum creatinine ≥ 2.0 mg/dL, estimated (eGFR) \< 30 mL/min/1.73 m² (CKD-EPI formula), or patients with end-stage renal disease or on dialysis.
  6. Presence of hepatocellular carcinoma, active , or cancer.
  7. History of or active bladder cancer.
  8. History of heart failure or current diagnosis of heart failure.
  9. Presence of terminal illnesses.
  10. History of gallstone disease, chronic pancreatitis, or acute pancreatitis.
  11. Underweight patients ( [BMI] \< 18.5 kg/m²).
  12. Pregnant women or women planning to become pregnant.
  13. Known to the active ingredients or of the study medications.
  14. History of diabetic ketoacidosis.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Pioglitazone

    Pioglitazone 15mg

    Drug: Empagliflozin 10 MG [Jardiance]

  • Experimental
    Empagliflozin

    Empagliflozin 10mg

    Drug: Pioglitazone 15 MG [Actos]

  • Experimental
    Pioglitazone & Empagliflozin

    Pioglitazone 15mg + Empagliflozin 10mg

    Drug: Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]

Interventions

  • DrugPioglitazoneStudies of PioglitazonePioglitazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive pioglitazone 15 mg, administered orally once daily. The tablet may be taken with or without food.

  • DrugEmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive empagliflozin 10 mg, administered orally once daily. The tablet may be taken with or without food.

  • DrugEmpagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]

    Drug page: EmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive one tablet of pioglitazone 15 mg and one tablet of empagliflozin 10 mg, administered orally once daily. Both tablets may be taken with or without food.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving HbA1c Treatment Targets

    Percentage of participants who achieve the predefined HbA1c treatment goal at 24 weeks.

    Time frame: 24 weeks

  2. Change in Fibroscan Controlled Attenuation Parameter (CAP) Score

    Assessment of changes in hepatic steatosis as measured by the controlled attenuation parameter (CAP) score using Fibroscan technology over a 24-week period.

    Time frame: 24 weeks

Secondary outcomes

  1. Change in HbA1c Levels

    Change in glycated hemoglobin (HbA1c) from baseline after 24 weeks of treatment.

    Time frame: 24 weeks

  2. Change in Liver Stiffness Measurement

    Change in liver stiffness measurement (LSM) assessed using Fibroscan

    Time frame: 24 weeks

  3. Change in Non-Invasive Blood-Based Fibrosis Markers

    Change in NAFLD score, Fibrosis-4 (FIB-4) index, and AST to Platelet Ratio Index (APRI) over 12 and 24 weeks.

    Time frame: 12 weeks, 24 weeks

  4. Change in Anthropometric Measures

    Changes in metabolic parameters including body weight, body mass index (BMI), waist circumference

    Time frame: 12 weeks, 24 weeks

  5. Change in Lipid Parameters

    Changes in blood lipid profile (total cholesterol, LDL-c, HDL-c, triglycerides)

    Time frame: 12 weeks, 24 weeks

  6. Change in Liver Function Tests

    Change in liver function markers including AST, ALT, gamma-glutamyl transferase (gamma-GT), albumin, bilirubin, and prothrombin time

    Time frame: 12 weeks, 24 weeks

  7. Change in Fibrosis Biomarker

    Change in serum type IV collagen levels

    Time frame: 12 weeks, 24 weeks

  8. Change in Inflammatory Biomarker

    Change in high-sensitivity C-reactive protein (hs-CRP) levels

    Time frame: 12 weeks, 24 weeks

Other outcomes

  1. Change in Other Blood Biomarkers

    Change in ketone body levels

    Time frame: 24 weeks

  2. Change in Proteinuria

    Change in urinary albumin-to-creatinine ratio, protein-to-creatinine ratio

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 23 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 25, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06989723
Collaborators
Celltrion
Responsible party
Soo Lim (Clinical Professor and Principal Investigator, Division of Endocrinology, Seoul National University Bundang Hospital) — Principal investigator
First posted
May 25, 2025
Start date
Jan 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 25, 2025

Study contacts

Soo Lim Dr, MD PhD
Contact
limsoo@snu.ac.kr
+82-31-787-7035
Minji Sohn Dr, PhD
Contact
rainbowmjs@naver.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Empagliflozin

Start the discussion